Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework

The Lancet Psychiatry

Volumn 4, Issue 9, 2017, Pages 725-732

  Gold, Stefan M ^a,b   Enck, Paul ^c   Hasselmann, Helge ^a   Friede, Tim ^d   Hegerl, Ulrich ^e   Mohr, David C ^f   Otte, Christian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR THERAPY; CLINICAL DECISION MAKING; CONTROL GROUP; EFFECT SIZE; HEALTH CARE POLICY; HUMAN; INTERNAL VALIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STUDY DESIGN; DECISION MAKING; METHODOLOGY; PROCEDURES;

BEHAVIOR THERAPY; CONTROL GROUPS; DECISION MAKING; HUMANS; PSYCHIATRY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 85017148397     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30153-0     Document Type: Review

References (33)

1. The Lancet Psychiatry. A level playing field. Lancet Psychiatry, 1, 2014, 403.
2. The Lancet Psychiatry. Signal to noise: the trouble with psychiatry trials. Lancet Psychiatry, 3, 2016, 305.
3. Mohr, DC, Spring, B, Freedland, KE, et al. The selection and design of control conditions for randomized controlled trials of psychological interventions. Psychother Psychosom 78 (2009), 275–284.
4. Mohr, DC, Ho, J, Hart, TL, et al. Control condition design and implementation features in controlled trials: a meta-analysis of trials evaluating psychotherapy for depression. Transl Behav Med 4 (2014), 1–17.
5. Liegl, G, Plessen, CY, Leitner, A, Boeckle, M, Pieh, C, Guided self-help interventions for irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 27 (2015), 1209–1221.
6. Relton, C, Torgerson, D, O'Cathain, A, Nicholl, J, Rethinking pragmatic randomised controlled trials: introducing the ‘cohort multiple randomised controlled trial’ design. BMJ, 340, 2010, c1066.
7. Furukawa, TA, Noma, H, Caldwell, DM, et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand 130 (2014), 181–192.
8. Patterson, B, Boyle, MH, Kivlenieks, M, Van Ameringen, M, The use of waitlists as control conditions in anxiety disorders research. J Psychiatr Res 83 (2016), 112–120.
9. Cuijpers, P, Cristea, IA, Karyotaki, E, Reijnders, M, Huibers, MJH, How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry 15 (2016), 245–258.
10. Schedlowski, M, Enck, P, Rief, W, Bingel, U, Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev 67 (2015), 697–730.
11. Weimer, K, Colloca, L, Enck, P, Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2 (2015), 246–257.
12. Khan, A, Kolts, RL, Rapaport, MH, Krishnan, KR, Brodhead, AE, Browns, WA, Magnitude of placebo response and drug–placebo differences across psychiatric disorders. Psychol Med 35 (2005), 743–749.
13. Hegerl, U, Allgaier, AK, Henkel, V, Mergl, R, Can effects of antidepressants in patients with mild depression be considered as clinically significant?. J Affect Disord 138 (2012), 183–191.
14. Sneed, JR, Rutherford, BR, Rindskopf, D, Lane, DT, Sackeim, HA, Roose, SP, Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry 16 (2008), 65–73.
15. Sinyor, M, Levitt, AJ, Cheung, AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71 (2010), 270–279.
16. Furukawa, TA, Weitz, ES, Tanaka, S, et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-analysis of pill-placebo-controlled trials. Br J Psychiatry 210 (2017), 190–196.
17. Hegerl, U, Hautzinger, M, Mergl, R, et al. Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm. Int J Neuropsychopharmacol 13 (2010), 31–44.
18. Rutherford, BR, Mori, S, Sneed, JR, Pimontel, MA, Roose, SP, Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res 46 (2012), 697–702.
19. Otte, C, Gold, SM, Penninx, BW, et al. Major depressive disorder. Nat Rev Dis Prim, 2, 2016, 16065.
20. Ioannidis, JPA, Most psychotherapies do not really work, but those that might work should be assessed in biased studies. Epidemiol Psychiatr Sci 25 (2016), 436–438.
21. Freedland, KE, Mohr, DC, Davidson, KW, Schwartz, JE, Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med 73 (2011), 323–335.
22. Kolovos, S, van Tulder, MW, Cuijpers, P, et al. The effect of treatment as usual on major depressive disorder: a meta-analysis. J Affect Disord 210 (2017), 72–81.
23. Craig, P, Dieppe, P, Macintyre, S, Michie, S, Nazareth, I, Petticrew, M, Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ, 337, 2008, a1655.
24. Ford, I, Norrie, J, Pragmatic trials. N Engl J Med 375 (2016), 454–463.
25. Friede, T, Kieser, M, Sample size recalculation in internal pilot study designs: a review. Biometrical J 48 (2006), 537–555.
26. Schlömer, P, Brannath, W, Group sequential designs for three-arm ‘gold standard’ non-inferiority trials with fixed margin. Stat Med 32 (2013), 4875–4889.
27. Chataway, J, Nicholas, R, Todd, S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler J 17 (2011), 81–88.
28. Friede, T, Parsons, N, Stallard, N, et al. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis. Stat Med 30 (2011), 1528–1540.
29. Cuijpers, P, Cristea, IA, How to prove that your therapy is effective, even when it is not: a guideline. Epidemiol Psychiatr Sci 25 (2016), 428–435.
30. Elliott, SA, Brown, JSL, What are we doing to waiting list controls?. Behav Res Ther 40 (2002), 1047–1052.
31. Huhn, M, Tardy, M, Spineli, LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 71 (2014), 706–715.
32. Adli, M, Hegerl, U, Do we underestimate the benefits of antidepressants?. Lancet 383 (2014), 1361–1362.
33. Cuijpers, P, Karyotaki, E, Andersson, G, Li, J, Mergl, R, Hegerl, U, The effects of blinding on the outcomes of psychotherapy and pharmacotherapy for adult depression: a meta-analysis. Eur Psychiatry 30 (2015), 685–693.